Antiviral protein

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Retrieved on: 
Monday, May 24, 2021
Antiviral drugs, Medical specialties, Biology, Interferon, Branches of biology, Broad-spectrum antiviral drug, Variants of SARS-CoV-2, Antiviral protein, COVID-19 drug repurposing research

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Retrieved on: 
Monday, May 24, 2021
Antiviral drugs, Medical specialties, Biology, Interferon, Branches of biology, Broad-spectrum antiviral drug, Variants of SARS-CoV-2, Antiviral protein, COVID-19 drug repurposing research

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.

Scientists Still Relentlessly Working to Develop Newest, More Advanced Antiviral Therapies for COVID-19 Treatments

Retrieved on: 
Wednesday, January 27, 2021
Health, Medicine, Biocides, Antiviral drugs, Virus, Influenza, Antiviral protein, COVID-19 drug development

Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses and, of course, COVID-19.

Key Points: 
  • Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses and, of course, COVID-19.
  • Scientists and researchers are relentlessly working to develop additional investigational antiviral compounds to treat COVID-19.
  • In addition, the COVID-19 emergency period has had a positive impact on the global antiviral therapies market growth in 2020.
  • This growth is majorly owing to rising R&D activities to find suitable antiviral drug for the coronavirus treatment.

Scientists Still Relentlessly Working to Develop Newest, More Advanced Antiviral Therapies for COVID-19 Treatments

Retrieved on: 
Wednesday, January 27, 2021
Health, Medicine, Biocides, Antiviral drugs, Virus, Influenza, Antiviral protein, COVID-19 drug development

Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses and, of course, COVID-19.

Key Points: 
  • Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses and, of course, COVID-19.
  • Scientists and researchers are relentlessly working to develop additional investigational antiviral compounds to treat COVID-19.
  • In addition, the COVID-19 emergency period has had a positive impact on the global antiviral therapies market growth in 2020.
  • This growth is majorly owing to rising R&D activities to find suitable antiviral drug for the coronavirus treatment.